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Abstract
Objective: To explore the effects of atorvastatin on expression of cyclooxygenase-2 (COX-2) in
human pulmonary epithelial cells (A549).
Methods: A549 cells were incubated in DMEM medium containing lipopolysaccharide (LPS) in the
presence or absence of atorvastatin. After incubation, the medium was collected and the amount
of prostaglandin E2 (PGE2) was measured by enzyme-linked immunosorbent assay (ELISA). The cells
were harvested, and COX-2 mRNA and protein were analyzed by RT-PCR and western-blot
respectively.
Results: LPS increased the expression of COX-2 mRNA and production of PGE2 in a dose- and
time-dependent manner in A549. Induction of COX-2 mRNA and protein by LPS were inhibited
by atorvastatin in a dose-dependent manner. Atorvastatin also significantly decreased LPS-induced
production of PGE2. There was a positive correlation between reduced of COX-2 mRNA and
decreased of PGE2 (r = 0.947, P < 0.05).
Conclusion:  Atorvastatin down-regulates LPS-induced expression of the COX-2 and
consequently inhibits production of PGE2 in cultured A549 cells.
1. Introduction
Human pulmonary epithelial cell is one of major sources
of productive inflammatory biomediators, such as pros-
taglandin E2 (PGE2), interleukin-6 (IL-6), in respiratory
inflammatory diseases [1]. Cyclooxygenase-2 (COX-2) is
an inducible enzyme that is expressed in response to
inflammatory cytokines, and it is responsible for the syn-
thesis of pro-inflammatory PGs such as PGE2. Increased
expression of COX-2 and production of PGE2 have been
found in pulmonary inflammatory disorders [2].
Statins is a class of compounds that decreases cholesterol
synthesis via inhibition of 3-hydroxy-3methylglutaryl
coenzyme A (HMG-CoA) reductase. Recently, anti-
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inflammatory effects of statins have been described [3].
For example, Atorvastatin reduces expression of the COX-
2 in cultured vascular smooth muscle cells [4]. However,
it is not clear whether Atorvastatin also affects COX-2
expression in human pulmonary epithelial cells. Because
of importance of COX-2 in inflammatory respiratory dis-
eases, we tested the effects of Atorvastatin on lipopolysac-
charide (LPS)-induced expression of COX-2 in cultured
human pulmonary epithelial cells.
2. Methods
2.1 Materials
Human pulmonary epithelial cell line (A549) was pur-
chased from American Type Culture Collection (ATCC).
Medium DMEM, trypsin, fetal bovine serum (FBS) and
LPS were purchased from Sigma-Aldrich. ECL chemilumi-
nescence reagents, COX-2 polyclonal antibody were pur-
chased from Cayman Chemical Co. Anti-rabbit IgG,
horseradish peroxidase linked whole antibody was
obtained from Amersham LIFE SCIENCE. HECAMEG was
from Vegatec (Villejuif, France). Trizol and electrophore-
sis reagents were from Promag Co. Atorvastatin was a gift
from Beijing Honghui Medicine Co.
2.2 Cell culture
A549 cells were grown in DEME medium supplemented
with 5% FBS, 100 u/ml penicillin, 100 u/ml streptomycin,
and 50 µg/L amphotericin B. Cells were sub-cultured into
six-well plates and maintained until sub-confluence. The
medium was then replaced by a serum-free culture
medium for 24 h prior to the addition of LPS and/or other
reagents. The cells were then incubated with various con-
centrations of LPS for 9 h, or 10 µg LPS for different times.
For atorvastatin experiments, the cells were incubated in
the serum-free medium containing 10 µg LPS in the pres-
ence or absence of different concentrations of atorvastatin
for 9 h.
2.3 PGE2 assay
After incubation, the medium was collected for measure-
ment of PGE2. PGE2 was determined by enzyme-linked
immunosorbent assays (ELISA, Shanghai Sun Biomedical
Co. CV <10%).
2.4 RNA extraction, reverse transcription-polymerase 
chain reaction (RT-PCR)
COX-2 mRNA was measured by RT-PCR as previously
described [5]. Briefly, total RNA from different experimen-
tal conditions was obtained by Trizol method (Life tech-
nologies) and the concentration of RNA was determined
by an absorbance at 260 nm. For RT-PCR, 100 ng of RNA
from different experimental conditions was applied to the
access RT-PCR System. The following primers were used
for COX-2: forward: 5'-AAG CTG GGA AGC CTT CTC TA-
3' and reverse: 5'-TTT CCA TCC TTG AAA AGG CGC-3',
which yielded products of 342 bp (50 sec at 55°C for
annealing of the primers, 35 cycles), and CYCLOPHILIN
A: forward: 5'-ATG GTC AAC CCC ACC GTG TTC TTC G-
3' and reverse: 5'-CGT GTG AAG TCA CCA CCC TGA CAC
A-3', which yielded products of 206 bp (50 sec at 55°C for
annealing primers, 38 cycles). The DNA products from
RT-PCR reactions were analyzed on a 4% polyacrylamide-
urea gel in the same buffer. The polyacrylamide gels were
dried and scanned using the ImageQuant densitometer
(Gel Doc 2000, BioRad Co).
2.5 Western Blot analysis
After incubation, A549 cells were washed twice in phos-
phate-buffered saline, lysed in 200 µl lysis buffer (20 mM
Tris/HCL, pH 7.5, 20 mM HECAMEG, 1 mM benzami-
dine). Protein content was determined by a microbicin-
choninic acid assay (Pierce) with bovine serum albumin
as standard. Western blot analysis was performed as
described previously [6]. Briefly, the protein was sepa-
rated by electrophoresis on a 10% polyacrylamide gel at
180 V for 45 min. After transfer to nitrocellulose, the
membrane was blocked, incubated with a specific rabbit
polyclonal antibody against COX-2 (1:1000). The blots
were then incubated with a horseradish peroxidase-conju-
gated donkey anti-rabbit antibody (1:5000). Antibody
labeling was detected by enhanced chemiluminescence.
The films were scanned using an Arcus II Agfa scanner,
and densitometric analysis was performed using Sigma
Gel software.
2.6 Statistical analysis
Statistical analysis was performed with SPSS analysis
(SPSS10.0 Software). PGE2 and RT-PCR data are presented
as mean ± S.D., and the differences between the multiple
treatment groups were analyzed by the one-way ANOVA,
LSD test. Data were correlated by nonparametric Spear-
man's rank method. Probability values of 0.05 or less were
considered to be statistically significant.
3. Results
3.1 Dose- and time-dependent effects of LPS on COX-2 
mRNA expression and PGE2 production
To determine the concentration dependent effect of LPS,
A549 cells were incubated with various concentrations of
LPS for 9 h. RT-PCR analysis indicated that LPS increased
the expression of COX-2 mRNA in a concentration-
dependent manner (Figure 1A, top). Concentrations as
low as 5 µg/ml LPS were effective in inducing expression
of the COX-2 mRNA. To determine the time-dependent
effect, A549 cells were incubated with LPS (10 µg/ml) for
different times. The expression of COX-2 mRNA was
increased by LPS as early as 6 h, the earliest time point
tested. It reached a maximum induction by 9 h of incuba-
tion, and remained stable for at least 12 h, the longest
time tested (Figure 1B, middle). LPS also increased theRespiratory Research 2005, 6:27 http://respiratory-research.com/content/6/1/27
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A: Dose-dependent effect of LPS on COX-2 mRNA expression Figure 1
A: Dose-dependent effect of LPS on COX-2 mRNA expression. A549 cells were incubated with various concentrations of LPS 
for 9 h (top, * P < 0.05 vs LPS 5 µg/ml). B: Time-dependent effect of LPS on COX-2 mRNA expression. A549 cells were incu-
bated with LPS (10 µg/ml) for various times (middle, * P < 0.05 vs 6 hrs group;). C: Time- and dose-dependent effects of LPS 
on PGE2 production (bottom, * P < 0.05 vs non-LPS group; • P < 0.05 vs 5 µg/ml LPS group; # P < 0.01 vs non-LPS group;   P 
< 0.05 vs 6 h group). These data were representative of three separate experiments.
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production of PGE2, a major cyclooxygenase product in
A549 cells, in a time- and dose-dependent manner (Figure
1C, bottom). LPS (5 µg/ml) caused a 3-fold increase in
amount of PGE2, and increased PGE2 was also observed as
early as 6 h of incubation.
3.2 Effect of atorvastatin on LPS-induced expression of 
COX-2 mRNA and protein
To determine whether atorvastatin affect the LPS-induced
expression of COX-2, the cells were incubated with vari-
ous concentrations of atorvastatin for 9 h in the presence
of 10 µg/ml LPS. RT-PCR analysis indicated that LPS-
induced expression of the COX-2 mRNA was decreased
significantly by atorvastatin (Figure 2). Consistent with
this observation, LPS-induced expression of the COX-2
protein was also inhibited by atorvastatin (Figure 3). Ator-
vastatin inhibited LPS-induced expression of COX-2
mRNA and protein in a dose-dependent manner.
3.3 Effect of atorvastatin on LPD-induced PGE2 production
Because atorvastatin decreased the expression of COX-2
mRNA and protein, we determined whether it also blocks
PGE2 production. A549 cells were incubated with various
concentrations of atovastatin in the presence of 10 µg/ml
LPS for 9 hrs. After incubation, the medium was collected,
and the amount of PGE2 in the medium was detected by
Effect of atorvastatin on LPS-induced expression of COX-2  mRNA Figure 2
Effect of atorvastatin on LPS-induced expression of COX-2 
mRNA. A549 cells were treated with various concentrations 
of atorvastatin in the presence of LPS (10 µg/ml) for 9 h. 
After incubation, total RNA were extracted and assayed by 
RT-PCR. A representative gel. (top) and relative density of 
gel. (bottom) are shown. * P <0.05 vs non- atorvastatin.   P 
< 0.05 10 µM vs atorvastatin group; • P < 0.05 vs 15 µM ator-
vastatin group.
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Effect of atorvastatin on LPS-induced expression of COX-2  protein Figure 3
Effect of atorvastatin on LPS-induced expression of COX-2 
protein. A549 cells were treated as described in Figure 2. 
After incubation, the cells were harvested, and sonicated. 
COX-2 protein in the cell lysates was detected by Western-
blot using a specific antibody against COX-2. A representa-
tive western-blot gel. (top) and the density of COX-2 band 
(bottom) are shown. * P = 0.001 vs non atorvastatin;   P < 
0.05 vs 10 µM atorvastatin; • P < 0.05 vs 15 µM atorvastatin 
group.
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ELISA. As shown in Table 1, atorvastatin decreased LPS-
induced PGE2 production in a dose-dependent manner.
3.4 Correlations
According to Spearman's non-parametric rank correlation
method, data analysis revealed that atorvastatin-mediated
reduction of LPS-induced expression of COX-2 is corre-
lated with a decrease in PGE2 production (r = 0.947, P <
0.05).
3.5 Time-dependent effects of atorvastatin on LPS-
induced COX-2 expression and PGE2 production
We further investigated the time-dependent effect of ator-
vastatin on expression of COX-2 and PGE2 production.
A549 cells were incubated with 10 µM atorvastatin in the
presence of 10 µg/ml LPS for various times. Atorvastatin
decreased the expression of COX-2 mRNA, protein, and
PGE2 in a time-dependent manner (Figure 4). The result
showed the similar time-dependent patterns in atorvasta-
tin-mediated reduction of COX-2 mRNA, protein and
PGE2, further suggesting a relationship between COX-2
expression and PGE2 production.
4. Discussion
Inflammatory cytokines as well as prostaglandins (PGs)
play important roles in inflammatory process of respira-
tory system [7]. PGs are synthesized from arachidonic acid
by a reaction catalyzed by cyclooxygenase. Two isoforms
of this enzyme have been identified [8]. COX-1 is
expressed constitutively in almost all tissues [9], and
COX-2 is an inducible enzyme that is expressed in
response to inflammatory cytokines [10]. Increased
expression of COX-2 has been reported in human pulmo-
nary epithelial cells under experimental inflammatory
conditions [11]. In the present study, we also found that
LPS induces expression of COX-2 mRNA and PGE2 for-
mation in a dose- and time-dependent manner in A549
cells. These results suggested that expression of the COX-
2 could be induced in A549 cells. Because the COX-2 is
responsible for the synthesis of pro-inflammatory PGs
such as PGE2 [10,11], an increased expression of COX-2
might play an important role in respiratory inflammatory
processes.
HMG-CoA reductase inhibitors, which decrease the syn-
thesis of cholesterol, have been shown to decrease the
incidence of acute coronary events [12]. Recent studies
suggest that the beneficial effects of statins on clinical
events may be not related to its' effect on cholesterol syn-
thesis. Statins affect endothelial cells, smooth muscle
cells, monocyte- macrophage, vasomotor function,
inflammatory responses, and plaque stability [13,14].
Anti-inflammatory action of statins might be related to
the reduction of the production of pro-inflammatory
cytokines. Statins inhibit the Ang II-induced secretion of
interleukin-6 (IL-6) in cultured human vascular smooth
muscle cells, and decrease production of IL-6, interleukin-
1β  in human umbilical vein endothelial cells [15].
Atorvaststin also down-regulates expression of COX-2
mRNA both in vivo and in vitro [4]. In this study, we found
that atorvastatin significantly reduced LPS-induced
expression of COX-2 mRNA in cultured A549 cells.
Atorvastatin also significantly reduced LPS-induced PGE2
Table 1: The effects of atorvastatin on amount of PGE2 production
LPS (10 µg/ml)
Atorvastatin 0 10 µM1 5   µM2 0   µM
PGE2 (pg/ml) 58.3 ± 2.8 46.1 ± 3.0* 31.2 ± 0.7* 31.7 ± 3.6*
* P < 0.05 vs non-atorvastatin.
Time-dependent effects of atorvastatin on LPS-induced  expression of COX-2 mRNA (red line), COX-2 protein  (green line) and PGE2 production (blue line) Figure 4
Time-dependent effects of atorvastatin on LPS-induced 
expression of COX-2 mRNA (red line), COX-2 protein 
(green line) and PGE2 production (blue line). The A549 cells 
were incubated with 10 µM atorvastatin in the presence of 
LPS (10 µg/ml) for different times. After incubation, COX-2 
mRNA and protein were analyzed by RT-PCR and western-
blot respectively, and the amount of PGE2 in the medium 
was determined by ELISA. Percent inhibitions by atorvastatin 
are shown.
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production. The correlation analysis indicated that there
is a positive correlation between reduced expression of
COX-2 and decreased PGE2. Furthermore, the patterns
showing effects of atorvastatin on LPS-induced expression
of COX-2 mRNA, protein and PGE2 production in differ-
ent times were similar. These suggest that decreased pro-
duction of PGE2  by atorvastatin is caused by down-
regulation of COX-2 expression. In contrast to our obser-
vations, other study [16] showed that mevastatin and lov-
astatin increase expression of COX-2 and subsequent
prostacyclin formation in human aortic smooth muscle
cells. It appears that the effects of statins on expression of
COX-2 might depend on the cell types or different statins
used.
In conclusion, atorvastatin down-regulates LPS-induced
expression of COX-2 and production of PGE2 in cultured
A549 cells. These results suggest that HMG-CoA reductase
inhibitors might have beneficial effects against respiratory
inflammation.
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